Botanix Pharmaceuticals (ASX:BOT) — Material Events
ASX:BOT · 13 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Botanix Grows Sofdra Prescriptions 5 Percent Amid $45M Capital Boost and Supply Chain ShiftMedium
Botanix reports Sofdra prescription growth, $45M capital raise, API supply deal with Piramal, and tariff risk mitigation
29 Apr 2026
·Quarterly Activity and Cash Flow Report
·85
Botanix Raises A$45 Million to Secure Supply Chain and Boost Sofdra GrowthMedium
Botanix secures A$45 million capital raise to fund API purchases and growth initiatives
17 Feb 2026
·Capital Raising
·85
Botanix Boosts Sofdra Sales 171% but Posts $33M Half-Year LossMedium
Botanix reports strong Sofdra sales growth and $16.5M revenue but posts $33.2M half-year loss; $45M capital raise underway
27 Feb 2026
·Appendix 4D - Interim Results Half Year Report
·85
Botanix Reports $5.76M Revenue Amid $86.4M Loss as Sofdra Launch AcceleratesHigh
Botanix reports $5.76M revenue, $86.4M loss as Sofdra commercialisation ramps up
29 Aug 2025
·Annual Report & Appendix 4E
·85
Botanix Sofdra Sales Surge 28% Amid Strategic Sales Force ExpansionMedium
Botanix Pharmaceuticals Q2 FY26: Sofdra sales surge 28%, sales force expansion, strong cash position
27 Jan 2026
·Quarterly Activity and Appendix 4C Cash Flow Report
·85
Botanix Boosts Sofdra Sales 50% with Expanded US Sales ForceMedium
Botanix reports 50% prescription growth, 65% revenue increase, and sales force expansion in Q1 FY26
20 Oct 2025
·Quarterly Activity Report and Appendix 4C
·85
Botanix Pharmaceuticals Raises A$45 Million to Fuel Sofdra® Growth and Cut API CostsHigh
Botanix Pharmaceuticals launches A$45 million capital raising amid strong Sofdra® growth and API cost reduction efforts
17 Feb 2026
·Capital Raising Presentation
·85
Botanix’s Sofdra Sales Surge Fuels $40M Capital Raise and $30M Debt FacilityHigh
Botanix’s Sofdra™ sales surge; $40M capital raise and $30M debt facility bolster cash position
28 July 2025
·Quarterly Activity Report and Appendix 4C
·85
Botanix Signs Term Sheet with Second API Supplier to Cut Costs and Secure Supply ChainMedium
Botanix Signs Term Sheet with Second API Supplier to Cut Costs and Secure Supply Chain
16 Apr 2026
·Term Sheet Agreement Announcement
·75
Botanix’s ECCLOCK® Gel Gains South Korean Approval, Launch Set for 2026Medium
Botanix's ECCLOCK® gel approved in South Korea, launch planned Q1 2026
5 Sept 2025
·Regulatory Approval Announcement
·70
Botanix Secures European Patent Nod for Sofdra Applicator TechnologyMedium
Botanix receives EPO Intention to Grant patent for Sofdra applicator technology
7 July 2026
·Patent Grant Announcement
·70
Botanix Defers Key API Purchases, Bolsters Capital for Sofdra ExpansionMedium
Botanix defers API purchases, strengthens capital for Sofdra launch, seeks additional supplier
30 Mar 2026
·Contract Amendment
·65
No articles in this tier for the last 12 months.
Market Mentions
8
- appeared in market wrap coverage
These are market wrap articles where Botanix Pharmaceuticals (ASX:BOT) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 28 (6 July -> 10 July) 2026
11 July 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026
Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026